Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

August 15, 2022

China’s NMPA approves InnoCare’s orelabrutinib to treat Marginal Zone Lymphoma

China’s National Medical Products Administration (NMPA) Centre for Drug Evaluation (CDE) has accepted InnoCare Pharma’s supplemental New Drug Application (sNDA) for orelabrutinib to treat relapsed or refractory Marginal Zone Lymphoma (R/R MZL).

China’s NMPA approves InnoCare’s orelabrutinib to treat Marginal Zone Lymphoma